Philips Expands Its Digital Pathology Solutions Portfolio with the Acquisition of PathXL
June 21 2016 - 08:00AM
Business Wire
Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has
acquired PathXL, a Northern Ireland-based leader in digital
pathology image analysis, workflow software and educational tools.
PathXL’s image analysis and tissue pathology software will
complement Philips’ Digital Pathology Solutions offering, and help
expand the business’ leadership in this fast-growing field.
Financial details of the transaction were not disclosed.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160621005193/en/
Education using digital pathology (Photo:
Business Wire).
Pathology involves the examination of patient tissue samples and
plays a crucial role in the diagnosis and treatment of a wide
variety of diseases, including cancer. Philips is a pioneer and
leader in the digitization of pathology, a fast-growing area in
healthcare as pathology labs are under pressure to improve
throughput and efficiency, enhance quality and to deliver new
diagnostic tests for precision medicine.
“With this acquisition, we are accelerating our drive to support
global medical institutions in their transition to digitized
pathology workflows,” said Russ Granzow, General Manager of Philips
Digital Pathology Solutions. “Together with PathXL we see a unique
opportunity to amplify our combined technology leadership
positions. We will be able to offer an intelligent and integrated
solution that fulfills many needs in computational pathology,
education, workflow solutions and image analytics. These important
and growing disciplines within pathology will enable a high-quality
quantitative analysis of digital whole slide images.”
Digital pathology will enable pathologists to review and share
large sets of clinical data using image analytics with the aim to
help improve the quality of diagnosis and has the potential to
enable new therapies and ultimately improve patient outcomes.
Philips’ lntelliSite Pathology Solution* is an automated digital
pathology image creation, management and viewing system comprised
of an ultra-fast pathology slide scanner, an image management
system and dedicated software tools.
PathXL, founded in 2004 and headquartered in Belfast, Northern
Ireland, offers a range of digital pathology software applications
to research and education segments of pathology and bio-pharma
markets. The company has approximately 30 employees, offices in the
UK and USA and distributors across three continents.
* In the European Union, the Philips IntelliSite Pathology
Solution is CE Marked under the European Union's 'In Vitro
Diagnostics Directive' for in vitro diagnostic use. In Canada, the
Philips IntelliSite Pathology Solution is licensed by Health
Canada for in vitro diagnostic use. In the United States, the
Philips IntelliSite Pathology Solution is indicated for in vitro
diagnostic use for Manual Read of the Digital HER2 Application. The
Philips IntelliSite Pathology Solution is registered for in vitro
diagnostic use in Singapore and Middle East.
About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people’s health and enabling better outcomes across
the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to
deliver integrated solutions. The company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care.
Headquartered in the Netherlands, Philips’ health technology
portfolio generated 2015 sales of EUR 16.8 billion and employs
approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160621005193/en/
Philips Group CommunicationsSteve Klink, +31 6
10888824steve.klink@philips.comorPhilips Investor RelationsLeandro
Mazzoni, +31 20 5977055investor.relations@philips.com
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2023 to Mar 2024